Financials LUMIBIRD

Equities

LBIRD

FR0000038242

Advanced Medical Equipment & Technology

Market Closed - Euronext Paris 09:05:07 26/04/2024 pm IST 5-day change 1st Jan Change
12.4 EUR -1.59% Intraday chart for LUMIBIRD -11.43% +1.81%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 279.8 312.6 533.7 369.9 269.6 273.8 - -
Enterprise Value (EV) 1 261.6 320.6 548.6 422.4 269.6 345.5 329.4 306.3
P/E ratio 29.2 x 46.8 x 38.8 x 32.5 x - 18.5 x 14.2 x 11.8 x
Yield - - - - - - - -
Capitalization / Revenue 2.54 x 2.47 x 3.28 x 1.94 x 1.32 x 1.22 x 1.12 x 1.05 x
EV / Revenue 2.38 x 2.53 x 3.38 x 2.21 x 1.32 x 1.55 x 1.35 x 1.18 x
EV / EBITDA 12.5 x 13.5 x 16.8 x 13.5 x 7.47 x 8.33 x 6.74 x 5.53 x
EV / FCF 29.1 x 429 x 65.3 x -21.9 x - 28.3 x 19.8 x 12.9 x
FCF Yield 3.43% 0.23% 1.53% -4.57% - 3.53% 5.05% 7.77%
Price to Book 2.24 x 1.93 x 3.25 x 1.91 x - 1.32 x 1.2 x 1.09 x
Nbr of stocks (in thousands) 18,409 22,268 22,191 22,339 22,134 22,080 - -
Reference price 2 15.20 14.04 24.05 16.56 12.18 12.40 12.40 12.40
Announcement Date 31/03/20 16/03/21 17/03/22 14/03/23 12/03/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 110.1 126.7 162.5 191 203.6 223.6 244 260
EBITDA 1 20.97 23.7 32.6 31.3 36.1 41.5 48.85 55.35
EBIT 1 12.26 14.1 19.8 16.4 20.9 23.8 29.75 34.95
Operating Margin 11.14% 11.13% 12.18% 8.59% 10.27% 10.64% 12.19% 13.44%
Earnings before Tax (EBT) 1 10.57 7.2 17.6 14.4 7.5 19.6 25.9 32.4
Net income 1 8.82 5.6 13.9 11.4 7.1 15 19.65 23.65
Net margin 8.01% 4.42% 8.55% 5.97% 3.49% 6.71% 8.05% 9.1%
EPS 2 0.5200 0.3000 0.6200 0.5100 - 0.6700 0.8750 1.055
Free Cash Flow 1 8.975 0.747 8.4 -19.3 - 12.2 16.65 23.8
FCF margin 8.15% 0.59% 5.17% -10.1% - 5.46% 6.82% 9.15%
FCF Conversion (EBITDA) 42.79% 3.15% 25.77% - - 29.4% 34.08% 43%
FCF Conversion (Net income) 101.76% 13.34% 60.43% - - 81.33% 84.73% 100.63%
Dividend per Share - - - - - - - -
Announcement Date 31/03/20 16/03/21 17/03/22 14/03/23 12/03/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 S1 2022 Q2 2022 S1
Net sales 1 46.2 75.5 46 84
EBITDA - - - 11.2
EBIT - - - 2.5
Operating Margin - - - 2.98%
Earnings before Tax (EBT) - - - -
Net income - - - -
Net margin - - - -
EPS - - - -
Dividend per Share - - - -
Announcement Date 27/07/20 26/07/21 22/09/22 22/09/22
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - 8 14.9 52.5 - 71.7 55.7 32.6
Net Cash position 1 18.2 - - - - - - -
Leverage (Debt/EBITDA) - 0.3376 x 0.4571 x 1.677 x - 1.728 x 1.139 x 0.5881 x
Free Cash Flow 1 8.98 0.75 8.4 -19.3 - 12.2 16.7 23.8
ROE (net income / shareholders' equity) 8.18% 3.88% 8.02% 6.08% - 7.3% 8.75% 9.6%
ROA (Net income/ Total Assets) - - - 3.17% - 3.7% 4.6% 5.1%
Assets 1 - - - 359.8 - 405.4 427.2 463.7
Book Value Per Share 2 6.780 7.290 7.390 8.680 - 9.400 10.30 11.40
Cash Flow per Share 2 1.190 0.8600 1.180 1.360 - 1.500 1.800 2.000
Capex 1 11.3 12.3 18.2 20.7 - 19.3 19.9 20.3
Capex / Sales 10.25% 9.71% 11.2% 10.84% - 8.61% 8.16% 7.79%
Announcement Date 31/03/20 16/03/21 17/03/22 14/03/23 12/03/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
12.4 EUR
Average target price
17.75 EUR
Spread / Average Target
+43.15%
Consensus

Quarterly revenue - Rate of surprise